Biotechnology

OSR released FY2026 Q1 earnings on May 13 (EST), actual revenue USD 484.06 K (forecast USD 778.5 K), actual EPS USD -0.0939 (forecast USD -0.29)

OSR Holdings Signs Agreement to Acquire Full IP of Vaximm's VXM01

OSR released FY2025 Q4 earnings on March 31 (EST), actual revenue USD 381.27 K (forecast USD 761.27 K), actual EPS USD -0.1859 (forecast USD -0.1)

OSR released FY2025 Annual Earnings on March 31 (EST), actual revenue USD 2.906 M (forecast USD 3.419 M), actual EPS USD -0.9229 (forecast USD -0.97)

OSR Holdings Inc plans to acquire 16% controlling stake in SILLAJEN

OSR released FY2025 9 Months Earnings on November 12, 2025 (EST) with actual revenue of USD 2.525 M and EPS of USD -1.147

OSR released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 627.75K, actual EPS USD -0.1223

OSR released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 1.136M, actual EPS USD 0.02

OSR released FY2024 Semi-Annual Earnings on August 14, 2025 (EST), with actual revenue of USD 1.792M and EPS of USD -1.0017

OSR released FY2024 Q2 earnings on August 14 (EST), actual revenue USD 881.83 K, actual EPS USD -0.41

OSR released FY2025 Semi-Annual Earnings on August 14 (EST), actual revenue USD 1.897 M, actual EPS USD -0.8051

OSR Holdings Reports Q1 2025 Earnings: Net Sales Down 16%, Sees Increased R&D Expenses

OSR released FY2025 Q1 earnings on May 20 (EST), actual revenue USD 761.27K, actual EPS USD -1.0446

OSR released FY2024 Q1 earnings on May 20 (EST), actual revenue USD 910.23K, actual EPS USD -0.5967

OSR released FY2023 Annual Earnings on April 22 Post-Market (EST) with actual revenue USD 0 and actual EPS USD 0

OSR released FY2024 Q4 earnings on April 22, 2025 (EST), with actual revenue of USD -2.395 M and EPS of USD 0.474

OSR released FY2024 Annual Earnings on April 22 Post-Market (EST), actual revenue USD 3.53 M, actual EPS USD -4.7929

OSR released FY2023 Q4 earnings on April 22, 2025 (EST), with actual revenue of USD -2.421 M and EPS of USD 0

OSR released FY2024 9 Months Earnings on February 21, 2025 (EST), actual revenue USD 2.647 M, actual EPS USD -2.8526

OSR released FY2024 Q3 earnings on February 21, 2025 (EST) with actual revenue of USD 823 K and EPS of USD -1.56

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

OSRH

SBIO

LABU

ARKG

OSR Holdings, Inc. (NASDAQ:OSRH) has acquired the full VXM01 intellectual property portfolio from VAXIMM AG for $30 million. This acquisition centralizes ownership and enhances long-term royalty economics. The deal follows a previous licensing agreement with BCM Europe AG, which includes potential milestone payments of up to $815 million. The VXM01 program targets difficult-to-treat tumors and is expected to improve licensing flexibility and shareholder value.

StockTitan

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

VanEck Biotech ETF

OSR HOLDINGS INC C/WTS 09/02/2028 (TO PUR COM)

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction | OSRH Stock News

OSR Holdings, Inc. reported Q1 2026 results with revenue of $484.1K, down 36% from Q1 2025. The net loss attributable to owners was $(2.93M), an improvement from $(11.39M) a year ago. Diluted loss per share improved to $(0.08) from $(1.04). Despite the revenue decline, gross margin increased to 33%. RMC contributed 96.5% of revenue, while management plans to increase R&D spending to $2.5–3.0M per quarter in H2 2026. They are also exploring financing options to support operations and R&D.

TradingView

OSR Holdings, Inc. 1Q 2026: Revenue $484.1K, EPS $(0.08) — 10-Q Summary

OSR Holdings' CEO, Kuk Hyoun "Peter" Hwang, announced a commitment to not pursue a reverse stock split, emphasizing that it does not create shareholder value. The company aims to regain Nasdaq compliance through operational execution and strategic milestones, including a significant licensing agreement with BCM Europe AG worth up to $815 million. OSR Holdings is focused on delivering real value through its subsidiaries and maintaining transparency with shareholders. The CEO reassured stakeholders of the company's long-term potential and commitment to organic growth.

Nasdaq

Samsung Electronics Co., Ltd. Sponsored GDR

SINO CAP N4304

SINOPHARM

SINOPHARM(CNCM LTD)

Sinopharm Accord

Samsung Electronics 

CEO Statement to Shareholders | OSRH Stock News

OSR fell 19.19%; Gilead Sciences fell 2.57%, with a transaction volume of USD 644 million; Moderna rose 17.20%, with a transaction volume of USD 611 million; Insmed fell 4.03%, with a transaction volume of USD 416 million; AbbVie fell 0.95%, with a market capitalization of USD 355.4 billion

Price Alert

Gilead Sciences

Moderna

Insmed

Abbvie

U.S. stock market update: OSR Holdings down 19.19%, financial concerns suppress market reaction, buy rating fails to boost stock price

CCRN

ATRA

In Thursday's trading session, several health care stocks experienced significant movements. Agilon Health (AGL) surged 115.7% to $60.08 following its Q1 earnings report. Atara Biotherapeutics (ATRA) rose 92.23% to $9.9, while Cross Country Healthcare (CCRN) increased by 29.52% to $13.1. Other gainers included SenesTech (SNES) up 25.85% and OSR Holdings (OSRH) up 20.66%. Conversely, LosersenGene Therapeutics (ENGN) plummeted 79.7% to $1.79, and Entrada Therapeutics (TRDA) fell 58.86% to $6.59. Accuray (ARAY) and Pharming (PHAR) also saw declines of 28.73% and 27.6%, respectively.

benzinga_article

Cross Country Healthcare

agilon health

Atara Biotherap

Senestech

Ernexa Therapeutics

enGene Therapeutics

Entrada Therapeutics

Accuray

Pharming Group NV

Apimeds Pharmaceuticals US

Aspire Biopharma

ENGENE THERAPEUTICS INC C/WTS 31/10/2028 (TO PUR COM)

ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM)

12 Health Care Stocks Moving In Thursday's Intraday Session

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target | OSRH Stock News

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target | OSRH Stock News

OSR(OSRH.US)

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction | OSRH Stock News

OSR Holdings, Inc. 1Q 2026: Revenue $484.1K, EPS $(0.08) — 10-Q Summary

CEO Statement to Shareholders | OSRH Stock News

U.S. stock market update: OSR Holdings down 19.19%, financial concerns suppress market reaction, buy rating fails to boost stock price

12 Health Care Stocks Moving In Thursday's Intraday Session

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target | OSRH Stock News